Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2005 | Controversies

FDG imaging should be considered the preferred technique for accurate assessment of myocardial viability

Author: Jeroen J. Bax

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2005

Excerpt

The number of patients presenting with heart failure has been increasing exponentially. It was recently estimated that 4.9 million patients in the United States have chronic heart failure, with 550,000 new cases per year, resulting in 970,000 hospitalisations [1]. The underlying aetiology of heart failure is frequently coronary artery disease; Gheorghiade and Bonow estimated that more than 70% of patients with heart failure have underlying coronary artery disease [2]. …

American Heart Association (2005) Heart disease and stroke statistics, 2005 update. American Heart Association

Gheorghiade M, Bonow RO. Chronic heart failure in the United States. A manifestation of coronary artery disease. Circulation 1998;97:282–9PubMed

Bax JJ, Van der Wall EE, Harbinson M. Radionuclide techniques for the assessment of myocardial viability and hibernation. Heart 2004;90 Suppl 5:v26–33CrossRefPubMed

Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–8PubMed

Tamaki N, Yonekura Y, Yamashita K, Saji H, Magata Y, Senda M, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860–5CrossRefPubMed

Bax JJ, Patton JA, Poldermans D, Elhendy A, Sandler MP. 18-Fluorodeoxyglucose imaging with PET and SPECT: cardiac applications. Semin Nucl Med 2000;30:281–98PubMed

Marwick TH, Nemec JJ, Lafont A, Salcedo EE, MacIntyre WJ. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 1992;69:854–9CrossRefPubMed

Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995;92:3436–44PubMed

Haas F, Augustin N, Holper K, Wottke M, Haehnel C, Nekolla S, et al. Time course and extent of improvement of dysfunctioning myocardium in patients with coronary artery disease and severely depressed left ventricular function after revascularization: correlation with positron emission tomographic findings. J Am Coll Cardiol 2000;36:1927–34CrossRefPubMed

10.

Di Carli M, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527–33CrossRefPubMed

11.

Beanlands RSB, DeKemp R, Smith S, Johansen HL, Ruddy TD. F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function. Am J Cardiol 1997;79:1092–5CrossRefPubMed

12.

Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001;26:142–86

13.

Pagano D, Townend JN, Parums DV, Bonser RS, Camici PG. Hibernating myocardium: morphological correlates of inotropic stimulation and glucose uptake. Heart 2000;83:456–61CrossRefPubMed

14.

Matsunari I, Boning G, Ziegler SI, Nekolla SG, Stollfuss JC, Kosa I, et al. Attenuation-corrected^99mTc-tetrofosmin single-photon emission computed tomography in the detection of viable myocardium: comparison with positron emission tomography using¹⁸F-fluorodeoxyglucose. J Am Coll Cardiol 1998;32:927–35CrossRefPubMed

15.

Bax JJ, Wijns W. Fluorodeoxyglucose imaging to assess myocardial viability: PET, SPECT or gamma camera coincidence imaging? J Nucl Med 1999;40:1893–5PubMed

Title: FDG imaging should be considered the preferred technique for accurate assessment of myocardial viability
Author: Jeroen J. Bax
Publication date: 01-07-2005
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2005
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-1826-8

At a glance: The STEP trials

Springer Medicine

FDG imaging should be considered the preferred technique for accurate assessment of myocardial viability

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2005

Detection of multiple extracranial metastases from glioblastoma multiforme by means of whole-body [18F]FDG-PET

Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET

The physics of clinical MR taught through images. 2005

To use MIBI or not to use MIBI? That is the question when assessing tumour cells

The route of administration (oral vs intravenous) does not influence dose or outcome in Graves’ disease and unifocal autonomy

FDG imaging should be considered the preferred technique for accurate assessment of myocardial viability